Drug intelligence / Profile preview

NovaTIL

Development stage: Preclinical
Lead developer: NovaRx
Modality: Cell Therapies

Overview

NovaTIL is a Tumor-Infiltrating Lymphocyte (TIL) cancer immunotherapy developed by NovaRx. It was identified as a lead asset for metastatic melanoma. Viropro had intended to acquire NovaRx to support the advancement of NovaTIL's clinical programs, but the acquisition was not completed due to Viropro's funding challenges.

Beyond the preview

Go deeper on NovaTIL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NovaTIL.

Explore the full profile